Bausch Health(BHC) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Bausch Health reported a revenue of $2,796 million for Q4 2025, reflecting a 9% increase year-over-year on a reported basis [11] - Adjusted EBITDA for Q4 was $1,052 million, marking a 13% increase compared to the same quarter last year [11] - For the full year 2025, revenue grew by 7% on a reported basis and 6% on an organic basis [8] Business Line Data and Key Metrics Changes - Salix revenues in Q4 were $693 million, a 9% increase year-over-year [14] - Solta Medical segment revenues were $137 million, a slight decrease of 1% on a reported basis [16] - Diversified segment revenues increased by 12% to $255 million, primarily due to improved net pricing [17] Market Data and Key Metrics Changes - International segment revenues were $306 million, a 10% increase on a reported basis [15] - EMEA and LatAm markets showed double-digit growth, while Canada experienced a 6% contraction [15] - South Korea's revenue for Solta was up 40%, making it the largest revenue-generating geography for Solta in 2025 [16] Company Strategy and Development Direction - The company aims to enhance its operational assets through innovation and optimizing brand growth globally [23] - Bausch Health is focused on business development opportunities to expand its portfolio and maximize shareholder value [23] - The acquisition of Shibo's aesthetics business in China is expected to strengthen the company's market presence [8][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth, citing strong performance across markets and improved capital structure [6][7] - The company anticipates a stronger growth rate in the first half of 2026, with a revenue guidance of $5.25 billion to $5.4 billion [21][22] - Management acknowledged the disappointment regarding the RED-C trial results but remains committed to exploring new development opportunities [10] Other Important Information - The company achieved over $1 billion in adjusted operating cash flow and reduced net debt by approximately $320 million in Q4 [13][8] - A significant debt exchange improved the company's debt maturity profile by approximately $1.7 billion [8] Q&A Session Summary Question: What is the updated decision framework for the separation post RED-C readout? - Management stated there is no change in focus on debt repayment and reinvestment in the business despite disappointment in RED-C results [34] Question: Can you provide more details about business development plans? - Management is screening assets for potential acquisitions and leveraging their commercial team for growth opportunities [37][38] Question: What is the impact of higher-than-planned residual volume from Medicaid? - Most of the residual volume was associated with XIFAXAN, amounting to less than $50 million in revenue for Q4 [80] Question: What are the key events to watch regarding Xifaxan generics? - Management confirmed that a generic is expected in January 2028, with ongoing legal proceedings affecting exclusivity [86] Question: What is the expected EBITDA trajectory for 2027? - Management indicated that 2027 EBITDA would be around $2.7 billion, reflecting a dip compared to 2025 [88]